Towards Reducing The Susceptibility Of “high Risk” Infants To Allergic Asthma By Therapeutic Modulation Of Immunoregulatory Functions In The Pregnant Mother.
Funder
National Health and Medical Research Council
Funding Amount
$445,681.00
Summary
This project will deliver information in relation to the potential use and underlying modes of action of a therapeutic agent fed to pregnant mothers at high risk for atopic children, to protect against allergic asthma development in their offspring. Furthermore, the project will address the benefits of this therapeutic agent in relation to protection against inflammation induced preterm birth.
A Prospective, Open-label, Single-centre/multi-site, Randomized Clinical Trial Of A Novel Maternal Microbiological “screen & Treat” Program Compared With Normal Care For The Prevention Of Preterm Birth
Funder
National Health and Medical Research Council
Funding Amount
$1,708,561.00
Summary
In 2014, our team launched the world-unique Western Australian Preterm Birth (PTB) Prevention Initiative and reduced the rate of PTB state-wide by 8%. Our next step is to trial a “screen & treat” program to detect women in mid-pregnancy at high risk of infection-driven PTB and treat them with antimicrobial medications. The study will involve more than 6000 women and aims to lower the rate of spontaneous PTB rate by 30%, which if applied nationally, may prevent 4500 PTBs each year.
Maternal Recognition Of Fetal Sex In The Regulation Of Labour
Funder
National Health and Medical Research Council
Funding Amount
$455,821.00
Summary
Preterm birth is the largest cause of death in infants and males are more likely to be born preterm than females. We propose that the intrauterine renin-angiotensin system, the activity of which is regulated in a sex-specific manner, plays a critical role in protecting against preterm labour. Our study will further our understanding of the mechanisms of preterm labour and provide new insight into the sex-specific differences in the prevalence of preterm birth.
Inflammatory Pathways For Novel Therapeutic Interventions In Preterm Delivery
Funder
National Health and Medical Research Council
Funding Amount
$568,006.00
Summary
Preterm birth is common and carries severe risks for the child. Existing therapies are not very successful in arresting preterm labour or improving outcomes for the fetus. We have discovered that blocking inflammatory ‘sensor’ molecules can slow labour progression. This project will (1) increase our knowledge of the inflammatory pathways that initiate early labour, and (2) define the mechanism of action and safety of a new drug that has potential for delaying preterm birth in women.
Longitudinal Communication Outcomes Following Traumatic Brain Injury
Funder
National Health and Medical Research Council
Funding Amount
$798,171.00
Summary
Traumatic brain injury (TBI) is the leading cause of disability in young Australians. The condition frequently manifests in impaired verbal communication. Communication is essential to successful rehabilitation, and return to society. However, the critical time for delivery of optimal treatment for communication remains unknown. This prospective longitudinal study will examine communication recovery following (TBI) to identify predictors of recovery and the best time to offer treatment.
Evaluating “Standing Tall” – An Engaging Home-based Exercise Program Using Mobile Technology For Maximizing Long-term Adherence And Preventing Falls In Older People: Randomized Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$791,081.00
Summary
Current evidence suggests that older people have to exercise for two hours per week for six months to prevent falls, with a strong focus on balance exercises. We have developed and tested an engaging home-based balance training program delivered through mobile (tablet) technology, called ‘Standing Tall’. We propose a randomised controlled trial to examine the effectiveness of our program for preventing falls in 500 community-dwelling older people, in addition to adherence- and cost-analyses.
Implementing Multiple Imputation With Sensitivity Analysis In Large-scale Longitudinal Studies
Funder
National Health and Medical Research Council
Funding Amount
$473,507.00
Summary
Missing data arise in most research studies and if not handled appropriately can mean the study results are not correct. With researchers now conducting larger and longer studies the challenges posed by missing data are increasing. In this grant we study a powerful technique for handling missing data, which in its current form often cannot be applied effectively in large studies. By developing this approach we will improve the accuracy of results from large-scale epidemiological studies.
New Antimalarial Drug Leads Targeting Multiple Species And Life Cycle Stages
Funder
National Health and Medical Research Council
Funding Amount
$818,477.00
Summary
Malaria causes ~200 million clinical cases and >430,000 deaths annually. Prevention and treatment relies on drugs, however malaria parasite drug resistance is an enormous problem. To address this issue, and aim towards eliminating malaria, we need to develop new drugs. This project addresses this important health need by investigating the ability of new chemical compounds, developed at CSIRO, to kill human-infecting malaria parasites during different parts of their complicated lifecycles.
Developing Diagnostics And Therapeutics For Preeclampsia: Targeting A Novel Placental Specific SFlt-1 Variant
Funder
National Health and Medical Research Council
Funding Amount
$722,283.00
Summary
Preeclampsia is a dreaded disease of pregnancy, globally responsible for thousands of deaths of mothers and babies. It is caused by a protein called sFlt-1 leaking out of the placenta and attacking the mothers organs. Recently, a new sflt-1 subtype was discovered that is specific to the placenta. It may be the key disease causing toxin in preeclampsia. We will target this placental specific sFlt-1 to generate diagnostics to predict preeclampsia, and explore novel ways to block the toxic effects ....Preeclampsia is a dreaded disease of pregnancy, globally responsible for thousands of deaths of mothers and babies. It is caused by a protein called sFlt-1 leaking out of the placenta and attacking the mothers organs. Recently, a new sflt-1 subtype was discovered that is specific to the placenta. It may be the key disease causing toxin in preeclampsia. We will target this placental specific sFlt-1 to generate diagnostics to predict preeclampsia, and explore novel ways to block the toxic effects of sFlt-1 as a strategy to develop drugs.Read moreRead less
Nanomedicine Targeted Delivery Of Therapeutics To The Placenta To Treat Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$513,148.00
Summary
Preeclampsia, one of the most serious complications of pregnancy, affects around 3-8% of all pregnancies. Sadly, there is no treatment. We have developed a new technique to deliver treatments only to the placenta, sparing the mother and baby from side effects. We will test whether this technique can treat the source of preeclampsia, the placenta, in human and mouse models in our laboratory. This work has potential to offer possibilities of new treatments to other pregnancy complications.